This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Memo Therapeutics AG will receive CHF 10.5m (US $11.4m) from the Swiss government to clinicallydevelop a SARS-CoV-2 antibody against COVID-19, allowing it to start Phase 1 studies in Q1, 2022.
Biotechnology company Adcentrx Therapeutics has raised $38m in Series A+ financing to advance its pipeline of new antibody-drug conjugate (ADC) therapeutics into clinicaldevelopment. ADRX-070 is the company’s lead candidate and is anticipated to enter a first-in-human Phase I clinicaltrial in the second half of 2023.
SM17 is a humanised IgG4-k monoclonal antibody that targets IL-17RB to treat asthma, idiopathic pulmonary fibrosis (IPF), atopic dermatitis (AD) and other immunological disorders. SinoMab BioScience intends to commence a Phase I clinicaltrial in China to evaluate SM17’s safety profile.
Gilead Sciences has entered an exclusive option and partnership agreement with MacroGenics for developing bispecific antibodies. Under the deal, the companies will leverage MacroGenics’ DART platform to develop MGD024 as well as two further bispecific research programmes.
Upstream Bio will use the funds to advance its UPB-101 into Phase II trials to treat asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). It is also preparing for a swift transition to Phase III development. It targets the human thymic stromal lymphopoietin receptor to inhibit signalling.
In the ever-evolving landscape of pharmaceutical development, the complexity of early phase clinicaltrials is increasing. This surge in complexity is driven by escalating drug development costs, heightened competition and advanced scientific innovations. This is the storm that we find ourselves in the midst of.”
Sanofi and GlaxoSmithKline have begun clinicaltrials of their coronavirus vaccine, as AstraZeneca expanded studies of its rival into Japan. If trials go well the companies could request regulatory approval in the first half of 2021. Sanofi is leading the clinicaldevelopment and registration of the COVID-19 vaccine.
AbbVie is to begin clinicaldevelopment of an antibody designed to neutralise the SARS-CoV-2 coronavirus after licensing the therapy in from Harbour BioMed and Utrecht University. AbbVie has begun a phase 1 clinicaltrial of the antibody, with clinicaldevelopment beginning in the US and expanding into Europe.
The treatment is indicated for patients with no history of Factor VIII inhibitors and any detectable antibodies to adeno-associated virus serotype 5 (AAV5). The approval is based on comprehensive data from the clinicaldevelopment programme of Roctavian, including two-year findings from the international Phase III GENEr8-1 clinicaltrial.
Additionally, Astellas will obtain an exclusive option for licencing two clinical-stage programmes of Taysha, namely TSHA-102 and TSHA-120, for Rett syndrome and GAN, respectively. Astellas will also receive specific rights linked to any possible change of Taysha’s control.
Apexigen discovers and develops a new generation of antibody therapeutics to treat cancer, along with new immuno-oncology products to harness the immune system to combat and eradicate cancer.
Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted four new approvals for Merck ’s (MSD outside North America) humanised monoclonal antibody, Keytruda (pembrolizumab), to treat various types of cancers. Cervical cancer and melanoma indication are based on results from the KEYNOTE-826 and KEYNOTE-716 trials, respectively.
Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor, is currently undergoing clinicaltrials for the treatment of conditions including idiopathic pulmonary fibrosis, locally advanced unresectable pancreatic cancer, metastatic pancreatic cancer and Duchenne muscular dystrophy.
The proceeds from the business combination will be utilised to advance the pipeline of Disc to clinicaltrials and offer funding into 2025. Disc focuses on discovering and developing new therapies for patients with serious haematologic ailments. In-licensed from AbbVie in 2019, DISC-0974 is a monoclonal antibody.
Amlitelimab is under clinicaldevelopment by Kymab and currently in Phase II for Asthma. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. It is developed based on Kymouse technology.
Sanofi and Translate BIO have begun a clinicaltrial of their potential mRNA COVID-19 shot, as the French pharma struggles to keep pace with rivals despite its background in vaccines. A joint development team is working on a -20C storage temperature for late-stage clinicaldevelopment and at launch.
These study participants, representing approximately half of the total recruited participants in the trial, are being discontinued following violations of Good Clinical Practice (GCP) at certain clinicaltrial sites run by a third-party clinicaltrial site operator.
STRO-002 is under clinicaldevelopment by Sutro Biopharma and currently in Phase I for Refractory Acute Myeloid Leukemia. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.
Otsuka Pharmaceutical has announced positive interim results from its Phase III clinicaltrial for sibeprenlimab. Sibeprenlimab, which has a Breakthrough Therapy designation, is a monoclonal antibody that blocks APRIL ( A PR oliferation- I nducing L igand), a critical step in the immune cascade contributing to IgAN.
Genmab, a trailblazer in the field of antibody therapeutics, celebrates this milestone by reflecting on its impressive journey from a small-scale startup to a global leader in cancer treatment and beyond. Since then, innovative science has been at Genmab’s core, as we harness the power of human antibodies to improve the lives of patients.
Over the past decades, Myasthenia Gravis (MG) clinicaltrials have made remarkable progress in shining a light on this debilitating disease. Clinicaltrials in MG – What does history tell us? With a better understanding of the disease mechanisms, new target treatment options emerged in the 20th century.
Over the past decades, Myasthenia Gravis (MG) clinicaltrials have made remarkable progress in shining a light on this debilitating disease. Clinicaltrials in MG – What does history tell us? With a better understanding of the disease mechanisms, new target treatment options emerged in the 20th century.
Over the past decades, Myasthenia Gravis (MG) clinicaltrials have made remarkable progress in shining a light on this debilitating disease. Clinicaltrials in MG – What does history tell us? With a better understanding of the disease mechanisms, new target treatment options emerged in the 20th century.
ASP-2138 is under clinicaldevelopment by Xencor and currently in Phase I for Metastatic Adenocarcinoma of The Pancreas. Attributes of the drug, company and its clinicaltrials play a fundamental role in drug-specific PTSR and likelihood of approval. It is administered through intravenous drip route.
ASP-2138 is under clinicaldevelopment by Xencor and currently in Phase I for Gastric Cancer. Attributes of the drug, company and its clinicaltrials play a fundamental role in drug-specific PTSR and likelihood of approval. The therapeutic candidate is a bispecific antibody targeting CD3 and claudin 18.2
ASP-2138 is under clinicaldevelopment by Xencor and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction. Attributes of the drug, company and its clinicaltrials play a fundamental role in drug-specific PTSR and likelihood of approval. It is administered through intravenous drip route.
AT-1412 is under clinicaldevelopment by Kling Biotherapeutics and currently in Phase I for Solid Tumor. Attributes of the drug, company and its clinicaltrials play a fundamental role in drug-specific PTSR and likelihood of approval. It acts by targeting cells expressing CD9 epitope.
RZ-358 is under clinicaldevelopment by Rezolute and currently in Phase II for Hyperinsulinemia. Attributes of the drug, company and its clinicaltrials play a fundamental role in drug-specific PTSR and likelihood of approval. It was also under development for the treatment of insulinomas.
RZ-358 is under clinicaldevelopment by Rezolute and currently in Phase II for Hyperinsulinemia. Attributes of the drug, company and its clinicaltrials play a fundamental role in drug-specific PTSR and likelihood of approval. It was also under development for the treatment of insulinomas.
Kid EDV is under clinicaldevelopment by ImmunityBio and currently in Phase I for Pediatric Diffuse Intrinsic Pontine Glioma. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.
26, 2020 /PRNewswire/ — Cantargia AB (OMXS: CANTA) and BioInvent International AB (OMXS: BINV), today announced that BioInvent has been contracted as manufacturer of Cantargia’s antibody CAN10 in preclinical development for the treatment of systemic sclerosis and myocarditis. LUND, Sweden , Nov. About Cantargia.
Switzerland’s Numab has raised 100 million Swiss francs – around $110 million – in Series C financing to develop bispecific antibodies for cancer and inflammation, with Novo Noldings and HBM Partners co-leading the investor syndicate. The post Numab raises $110m to develop cancer bispecific antibodies appeared first on.
Amgen announced positive results from a Phase II clinicaltrial evaluating its investigational obesity drug MariTide (maridebart cafraglutide, formerly AMG 133) for the treatment of obesity and overweight in both diabetic and non-diabetic patients. percent in the 68-week STEP-1 clinicaltrial.
Izokibep is under clinicaldevelopment by Acelyrin and currently in Phase II for Panuveitis. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. It is developed based on affibody technology.
Annexuzlimab is under clinicaldevelopment by MedAnnex and currently in Phase I for Kidney Cancer (Renal Cell Cancer). GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.
The governing body claims this proposal could have positive effects on mitigating burdensome requirements for gene therapy clinicaltrials in the future. In this light, Pharma IQ’s weekly round-up focuses on advancing therapies and clinicaltrials to combat Covid-19.
Sanofi has joined a growing list of drugmakers going after alpha-synuclein targeting drugs for Parkinson’s disease, licensing a bispecific antibody from South Korea’s ABL Bio in a deal that could be worth more than $1 billion. Despite the interest, there have already been some failures in the alpha-synuclein category.
In alignment with Novavax’ commitment to transparency, Phase 3 clinicaltrial protocols are posted to the company’s website at Novavax.com/resources upon finalization. pivotal Phase 3 trial update. Novavax completed enrollment of 15,000 participants in a pivotal Phase 3 clinicaltrial being conducted in the U.K.
MCLA-129 is under clinicaldevelopment by Merus and currently in Phase II for Esophageal Squamous Cell Carcinoma (ESCC). GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.
Amgen announced positive results from a Phase II clinicaltrial evaluating its investigational obesity drug MariTide (maridebart cafraglutide, formerly AMG 133) for the treatment of obesity and overweight in both diabetic and non-diabetic patients. percent in the 68-week STEP-1 clinicaltrial.
Clinicaltrial to assess safety, immune response and reactogenicity, after preclinical data showed high neutralizing antibody levels. The Companies expect interim results from this trial in the third quarter of 2021. About the Phase 1/2 clinicaltrial. About previously-published preclinical results.
Gilead Sciences has made yet another rush into the oncology category, licensing a bispecific antibody from MacroGenics in development as a treatment for CD123-positive blood cancers, including acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS). Along with the signing fee, there is another $1.7 It brought in $4.7
Johnson & Johnson Posts Interim Results from Phase 1/2a ClinicalTrial of its Janssen COVID-19 Vaccine Candidate. Johnson & Johnson Posts Interim Results from Phase 1/2a ClinicalTrial of its Janssen COVID-19 Vaccine Candidate. Immune responses were similar across the age groups studied, including older adults.
Seagen specialises in developingantibody-drug conjugates (ADCs) which will complement Pfizer’s oncology portfolio. Seagen will maintain its operations in the Seattle area and will leverage Pfizer’s protein-engineering capabilities to develop next-generation biologics.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content